Company / Current Liabilities
PharmaCyte Biotech, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$2.9M
FY2025
5-year range
$586.6K / $7.4M
FY2021-FY2025
Trend
-60.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $580,248 in FY2017 to $7M in FY2024.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of +23.1%.
Increased from $586,581 to $3M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +60.5%
- 5-Year CAGR
- +23.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +23.1%, indicating consistent growth.
- In FY2025, current liabilities decreased 60.7% year-over-year.
- Peak current liabilities was recorded in FY2024.
- Lowest current liabilities in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.9M | -60.7% |
| FY2024 | $7.4M | +1165.2% |
| FY2023 | $586.6K | -16.7% |
| FY2022 | $704.4K | -2.8% |
| FY2021 | $724.8K | -29.7% |
| FY2020 | $1.0M | +38.8% |
| FY2019 | $742.9K | +15.3% |
| FY2018 | $644.2K | +11.0% |
| FY2017 | $580.2K | -9.0% |
| FY2016 | $637.6K | +70.6% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026